A Study of RO7821657 in Participants With Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D\[s\]) The study consists of two parts, namely Part 1 and Part 2: Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC). Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)
Epistemonikos ID: aa787736a8e46fb7f2e1c7741c4331e3efd1fbe9
First added on: Oct 21, 2026